Please login to the form below

Not currently logged in

Lilly's donanemab

This page shows the latest Lilly's donanemab news and features for those working in and with pharma, biotech and healthcare.

Eli Lillys Alzheimer’s drug denied FDA accelerated approval

Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval

Eli Lilly (Lilly) has announced that its experimental Alzheimer’s drug, donanemab, has not been granted accelerated approval by the US Food and Drug Administration (FDA) due to the company not ... Lilly announced in August 2022 that the FDA had

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...